Gurnari Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA mutated MDS and TP53 biallelic mutated MDS as specific entities. Notably, several ...
Fig. 74.1 Therapeutic flow chart for adult MDS patients with (very) low-risk or intermediate-risk IPSS-R scores @indicates nonfit (patients with multiple comorbidities and/or poor performance) or fit (patients with no comorbidities and good performance status). * indicates nontransplant strategies ...